Search results
Results from the WOW.Com Content Network
In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. [ 1 ]
Mitragynine is an indole-based alkaloid and is one of the main psychoactive constituents in the Southeast Asian plant Mitragyna speciosa, commonly known as kratom. [4] It is an opioid that is typically consumed as a part of kratom for its pain-relieving and euphoric effects.
A painting from 1681 depicting a person affected by nausea and vomiting. Cancer and nausea are associated in about fifty percent of people affected by cancer. [1] This may be as a result of the cancer itself, or as an effect of the treatment such as chemotherapy, radiation therapy, or other medication such as opiates used for pain relief.
Chemotherapy is a major cause of emesis, and often can cause severe and frequent emetic responses. This is because chemotherapy agents circulating in the blood activate the CTZ in such a way as to cause emesis. [13] Patients receiving chemotherapy are often prescribed antiemetic medications.
Mitragynine pseudoindoxyl is a μ-opioid receptor agonist and δ-opioid receptor antagonist.It is a G protein biased agonist at the μ-opioid receptor, which may be responsible for its favorable side effect profile compared to conventional opioids. [3]
7-Hydroxymitragynine (7-OH) is a terpenoid indole alkaloid from the plant Mitragyna speciosa, commonly known as kratom. [2] It was first described in 1994 [3] and is a human metabolite metabolized from mitragynine present in the Mitragyna speciosa. 7-OH binds to opioid receptors like mitragynine, but research suggests that 7-OH binds with greater efficacy.
Such placement may result from a multitude of considerations, including greater efficacy of other agents, socioeconomic considerations, availability issues, unpleasant side effects or similar issues relating to patient tolerance. Some experimental therapies might also be called drugs of last resort when administered following the failure of all ...
People with cancer may not report pain due to costs of treatment, a belief that pain is inevitable, an aversion to treatment side effects, fear of developing addiction or tolerance, fear of distracting the doctor from treating the illness, [51] or fear of masking a symptom that is important for monitoring progress of the illness.